Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs Cinpanemab (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Acronyms SPARK
  • Sponsors Biogen
  • Most Recent Events

    • 09 Oct 2018 Trial design presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders
    • 03 Oct 2018 According to a Biogen media release, data from this study will be presented at the upcoming International Congress of Parkinsons Disease and Movement Disorders (MDS)
    • 31 Aug 2018 Planned End Date changed from 30 Jun 2022 to 6 Apr 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top